Hans van der Vliet

Hans van der Vliet

Company: LAVA Therapeutics

Job title: Chief Scientific Officer


Bispecific Antibodies to Engage Vγ9Vδ2-T cells for Cancer Immunotherapy 2:30 pm

• Introduction to Vγ9Vδ2-T cells; a unique T cell subset with characteristics that make them well suited for a T cell engager approach. • The broad anticancer potential of tumor targeted activation of Vγ9Vδ2-T cells using a bispecific antibody approach is illustrated in various settingsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.